Skip to content

A study on changes in antiviral immune responses induced by lactic acid bacteria intake: A randomized, double-blind, placebo-controlled, parallel-group trial

A study on changes in antiviral immune responses induced by lactic acid bacteria intake: A randomized, double-blind, placebo-controlled, parallel-group trial - A study on changes in antiviral immune responses induced by lactic acid bacteria intake

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000060983
Enrollment
100
Registered
2026-03-20
Start date
2026-03-20
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy adults

Interventions

8-week daily intake of lactic acid bacteria 8-week daily intake of placebo (not containing lactic acid bacteria)

Sponsors

KSO Corporation
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1) Healthy Japanese males and females from 20 to 64 years old. 2) Individuals who self-identify as being susceptible to colds or influenza. 3) Individuals who received sufficient explanation of the purpose and details of the study, have the capacity to provide consent, fully understood the information, voluntarily agreed to participate, and provided written informed consent.

Exclusion criteria

Exclusion criteria: 1) Individuals with severe diseases such as diabetes, renal or hepatic disorders, cardiac diseases, thyroid disorders, adrenal disorders, psychiatric disorders, autoimmune diseases, or other metabolic diseases, or those currently undergoing treatment for these conditions (except for individuals deemed eligible by the principal investigator). 2) Individuals with chronic diseases who routinely take medication. 3) Individuals with atopic dermatitis, bronchial asthma, or chronic bronchitis. 4) Individuals who are unable to refrain from consuming foods containing lactic acid bacteria, bifidobacteria, oligosaccharides, or live microorganisms during the study period. 5) Individuals who plan to regularly visit a clinic or use prescription medications each year due to hay fever or allergic rhinitis. 6) Individuals with a history or current diagnosis of drug dependence or alcohol dependence. 7) Individuals with gastrointestinal diseases or a history of gastrointestinal surgery that may affect digestion or absorption (appendectomy excluded). 8) Individuals who are unable to discontinue supplements or health foods (including Foods for Specified Health Uses and Foods with Functional Claims) during the study period. 9) Individuals who are habitual smokers. 10) Individuals with extremely irregular dietary habits (e.g., one meal per day or insufficient nutritional intake). 11) Individuals with excessive alcohol consumption, defined as more than approximately 60 g of pure alcohol per day. 12) Individuals who are unable to abstain from alcohol for two days prior to the screening and each subsequent test visit. 13) Individuals who report having food allergies to any components of the study product. 14) Individuals engaged in shift work, night work, or physically demanding labor such as heavy lifting. 15) Individuals who go out less than twice a week. Due to character limitations, part of the exclusion criteria is presented in the 'Other Related Information' section.

Design outcomes

Primary

MeasureTime frame
Antiviral immune cell parameters

Secondary

MeasureTime frame
Cytokines Antiviral gene expression Cold-like symptoms questionnaire

Countries

Japan

Contacts

Public ContactMasanori Numazu

KSO Corporation Clinical Trial Management department

eigyou27@kso.co.jp03-3452-7733

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026